321 related articles for article (PubMed ID: 28516359)
1. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
[TBL] [Abstract][Full Text] [Related]
2. The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines.
Charalabidis A; Sfouni M; Bergström C; Macheras P
Int J Pharm; 2019 Jul; 566():264-281. PubMed ID: 31108154
[TBL] [Abstract][Full Text] [Related]
3. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
4. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
8. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
[TBL] [Abstract][Full Text] [Related]
9. Utilization of Diluted Compendial Media as Dissolution Test Solutions with Low Buffer Capacity for the Investigation of Dissolution Rate of Highly Soluble Immediate Release Drug Products.
Yoshida H; Abe Y; Tomita N; Izutsu KI
Chem Pharm Bull (Tokyo); 2020; 68(7):664-670. PubMed ID: 32612001
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Differences in Dosage Form Performance of Generics Using BCS-Based Biowaiver Specifications and Biopharmaceutical Modeling-Case Examples Amoxicillin and Doxycycline.
Hofsäss MA; Dressman J
J Pharm Sci; 2020 Aug; 109(8):2437-2453. PubMed ID: 32339527
[TBL] [Abstract][Full Text] [Related]
11. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples.
Papadopoulou V; Valsami G; Dokoumetzidis A; Macheras P
Int J Pharm; 2008 Sep; 361(1-2):70-7. PubMed ID: 18614303
[TBL] [Abstract][Full Text] [Related]
13. A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system.
Dokoumetzidis A; Macheras P
Int J Pharm; 2006 Sep; 321(1-2):1-11. PubMed ID: 16920290
[TBL] [Abstract][Full Text] [Related]
14. pH-Dependent Solubility and Dissolution Behavior of Carvedilol--Case Example of a Weakly Basic BCS Class II Drug.
Hamed R; Awadallah A; Sunoqrot S; Tarawneh O; Nazzal S; AlBaraghthi T; Al Sayyad J; Abbas A
AAPS PharmSciTech; 2016 Apr; 17(2):418-26. PubMed ID: 26202065
[TBL] [Abstract][Full Text] [Related]
15. Drug solubility in biorelevant media in the context of an inhalation-based biopharmaceutics classification system (iBCS).
Floroiu A; Loretz B; Krämer J; Lehr CM
Eur J Pharm Biopharm; 2024 Apr; 197():114206. PubMed ID: 38316234
[TBL] [Abstract][Full Text] [Related]
16. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio.
Rinaki E; Valsami G; Macheras P
Pharm Res; 2003 Dec; 20(12):1917-25. PubMed ID: 14725354
[TBL] [Abstract][Full Text] [Related]
17. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
18. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
19. The Evaluation of Valsartan Biopharmaceutics Properties.
de Castro LML; de Souza J; Caldeira TG; de Carvalho Mapa B; Soares AFM; Pegorelli BG; Della Croce CC; Barcellos NMS
Curr Drug Res Rev; 2020; 12(1):52-62. PubMed ID: 31820707
[TBL] [Abstract][Full Text] [Related]
20. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
Wei H; Löbenberg R
Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
